European Medicines Agency Update On Safety Of Insulin Glargine
The European Medicines Agency (EMEA) is looking into four recently published registry studies investigating a possible relationship between insulin analogues, in particular insulin glargine, and the risk of cancer. The studies were published on the Diabetologia website on 26 June 2009.
More: continued here
Filed under: Diabetes on June 30th, 2009
You must be logged in to post a comment.